Core Viewpoint - Zhongchao Inc. announced a 1-for-8 share consolidation to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market [1] Company Overview - Zhongchao Inc. is a platform-based internet technology company focused on providing services for patients with cancer and other major diseases [1] - The company is incorporated in the Cayman Islands and consolidates the financial results of its variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, through contractual arrangements [1] Share Consolidation Details - The share consolidation will take effect on March 2, 2026, with Class A ordinary shares trading under the same symbol "ZCMD" but with a new CUSIP number of G9897X123 [1] - Every eight Class A ordinary shares will be consolidated into one Class A ordinary share, and the same applies to Class B ordinary shares [1] - Prior to the consolidation, the company had 25,754,124 Class A and 4,999,772 Class B ordinary shares outstanding, which will reduce to approximately 3,219,267 Class A and 624,972 Class B ordinary shares post-consolidation [1] Shareholder Impact - The share consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the company's outstanding ordinary shares, except for adjustments from fractional shares [1] - The consolidation was approved by the company's shareholders and board of directors on February 10, 2026 [1]

| 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | ZCMD | 众巢医学 | 0.820 | -27.43% | -0.310 | 103.5万 | | LGCL | 周科任 | 0.1160 | -25.11% | -0.0389 | 189.38万 | | UPC | 大自然药业 | 7.220 | -23.68% | -2.240 | 326.25万 | | CLWT | 欧陆科仪 | 1.320 | -12.00% | -0.180 | 2.13万 | | ZYBT | 正业生物 | 2.720 | -11.69% | -0.360 | 97.44万 | 中概股收盘跌幅前五的个股为：众巢医学跌27.43%，罗科仕跌25.11%，大自然药业跌23.68%，欧陆科 仪跌12%，正业生物跌11.69%。(格隆汇) ...

Core Insights - Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates rather than new disclosures [1] Company Summaries - Zhongchao Inc. (ZCMD) saw a 14.04% increase in after-hours trading, rising to $1.30 from $1.14, despite no new filings or press releases [2] - AbCellera Biologics Inc. (ABCL) rose 11.41% in after-hours trading, closing at $6.64, following an 18.49% gain during the regular session, attributed to recent clinical trial progress [3][4] - Vor Biopharma Inc. (VOR) surged 9.53% in after-hours trading, recovering from a 19.42% drop during the regular session, with no new updates since a recent announcement regarding clinical data presentation [5] - Incannex Healthcare Inc. (IXHL) gained 6.48% in after-hours trading, partially recovering from a 6.94% drop, with the latest update showing positive Phase 2 trial results for PSX-001 [6] - Ovid Therapeutics Inc. (OVID) shares rose 8.03% in after-hours trading, building on a 5.38% gain during the regular session, with recent earnings report indicating a narrower net loss and higher revenue [7] - Bullfrog AI Holdings Inc. (BFRG) advanced 3.44% in after-hours trading, following a 3.57% rise during the regular session, after announcing an expansion of its sales and marketing team [8]

Revenue Performance - Total revenues for the six months ended June 30, 2025, were $5,601,079, a decrease of 32.7% compared to $8,348,329 for the same period in 2024[3] - Service revenues decreased to $4,910,889, down 25.6% from $6,595,083 in the prior year, while product revenues fell to $690,190, a decline of 60.7% from $1,753,246[3] Profitability - Gross profit for the six months ended June 30, 2025, was $2,709,724, representing a gross margin of 48.4%, compared to a gross profit of $4,737,096 and a margin of 56.7% in 2024[3] - The net loss attributable to Zhongchao Inc.'s shareholders for the six months ended June 30, 2025, was $965,254, compared to a net income of $90,047 in the same period of 2024[3] - The comprehensive loss attributable to Zhongchao Inc.'s shareholders for the six months ended June 30, 2025, was $591,928, compared to a loss of $366,974 in 2024[3] - Net loss for the six months ended June 30, 2025, was $862,319 compared to a net income of $182,933 for the same period in 2024[7] Operating Expenses - Operating expenses totaled $3,589,173, a decrease of 25.1% from $4,788,646 in the previous year, primarily due to reduced selling and marketing expenses[3] Cash and Assets - Cash and cash equivalents increased to $8,912,022 as of June 30, 2025, up 13.6% from $7,841,306 at the end of 2024[2] - Total current assets rose to $19,117,935, an increase of 2.2% from $18,707,217 as of December 31, 2024[2] - Cash and cash equivalents at the end of the period rose to $8,912,022 from $6,279,809 in the prior year[7] Liabilities - Total liabilities increased to $2,558,665, up 47.6% from $1,733,900 at the end of 2024[2] Shareholder Information - The weighted average number of ordinary shares outstanding for the six months ended June 30, 2025, was 25,388,903, compared to 2,637,340 in the prior year[3] Cash Flow and Investments - Net cash provided by operating activities increased to $1,820,881 from $809,598 year-over-year[7] - Net cash used in investing activities was $(980,271), compared to $(1,797,664) in the prior year[7] - Investments in short-term investments totaled $6,121,512, while proceeds from redemption of short-term investments were $5,241,241[7] Other Financial Metrics - Accounts receivable increased by $992,889, while accounts payable decreased by $396,025 compared to the previous year[7] - Cash paid for income tax increased to $89,807 from $67,043 year-over-year[7] - Depreciation and amortization expenses rose to $155,946 from $94,574 in the previous year[7] - Provision for expected credit losses was $291,227, up from $117,820 year-over-year[7] - The effect of exchange rate changes on cash and cash equivalents resulted in an increase of $230,106[7]

Core Insights - ZCMD's stock price increased by 21.72% to $1.05 per share, with a total market capitalization of $26.51 million as of August 26 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $15.86 million, representing an 18.37% year-over-year decline [1] - The net profit attributable to the parent company is expected to be -$0.6432 million, showing a significant improvement of 94.33% year-over-year [1] Company Overview - ZCMD is a Cayman Islands-registered holding company established on April 16, 2019, and operates through its subsidiary, ZCMD Medical Technology (Shanghai) Co., Ltd. [1] - The company focuses on medical education and patient education, offering three main business segments: 1. Medical MOOCs, 2. Sunshine Health Classroom, 3. Patient Assistance Program [1] - The Medical MOOCs platform combines advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced an 11.25% increase in stock price, reaching $0.96 per share, with a total market capitalization of $24.23 million as of August 25 [1] Financial Performance - For the fiscal year ending December 31, 2024, Zhongchao Medical reported total revenue of $15.86 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a significant year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical was established on April 16, 2019, as an offshore holding company registered in the Cayman Islands, with its operations managed by its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The company operates a digital medical education platform called Medical MOOC, which integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]

Core Insights - ZCMD's stock opened up by 5.44% on August 22, reaching $0.95 per share with a total market capitalization of $23.99 million [1] - For the fiscal year ending December 31, 2024, ZCMD reported total revenue of $15.86 million, a year-over-year decrease of 18.37%, while the net profit attributable to the parent company was -$0.6432 million, reflecting a year-over-year increase of 94.33% [1] Company Overview - ZCMD is a Cayman Islands-registered holding company established on April 16, 2019, and operates through its subsidiary, ZCMD Medical Technology (Shanghai) Co., Ltd [1] - The company offers a digital medical education platform called Medical MOOC, which integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - ZCMD focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Patient Assistance Program [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced a stock price increase of 2.44% on August 22, reaching $0.91 per share, with a total market capitalization of $22.99 million [1] Financial Performance - As of December 31, 2024, Zhongchao Medical reported total revenue of $15.86 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical was established on April 16, 2019, as an offshore holding company registered in the Cayman Islands, operated by its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The company offers a digital medical education platform called Medical MOOC, which combines advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced a stock price increase of 6.52% on August 19, reaching $0.98 per share, with a total market capitalization of $24.7488 million [1] Financial Performance - As of December 31, 2024, Zhongchao Medical reported total revenue of $15.8648 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical is a foreign holding company registered in the Cayman Islands on April 16, 2019, and operates through its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The subsidiary's platform, Medical MOOC, integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced a 4.06% increase in stock price, reaching $1.00 per share, with a total market capitalization of $25.25 million as of August 14 [1] Financial Performance - For the fiscal year ending December 31, 2024, Zhongchao Medical reported total revenue of $15.86 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a significant year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical was established on April 16, 2019, as an offshore holding company registered in the Cayman Islands, with its operations managed by its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The company operates a digital medical education platform called Medical MOOC, which integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]